Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded up 7.5% during trading on Monday . The stock traded as high as $12.70 and last traded at $12.31, with a volume of 59,072 shares changing hands. The stock had previously closed at $11.45.

Several equities research analysts recently commented on the company. HC Wainwright assumed coverage on Syros Pharmaceuticals in a research note on Monday, July 18th. They issued a “neutral” rating and a $10.00 price target for the company. Cowen and Company assumed coverage on Syros Pharmaceuticals in a research note on Monday. They issued an “outperform” rating for the company. JMP Securities assumed coverage on Syros Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $22.00 price target for the company. Wedbush assumed coverage on Syros Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Piper Jaffray Cos. assumed coverage on Syros Pharmaceuticals in a research note on Monday. They issued an “overweight” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $17.50.

The company’s 50 day moving average is $0.00 and its 200 day moving average is $0.00. The stock’s market capitalization is $117.55 million.

In related news, major shareholder Redmile Group, Llc acquired 432,746 shares of the firm’s stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $5,409,325.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Nelsen acquired 400,000 shares of the firm’s stock in a transaction dated Wednesday, July 6th. The stock was bought at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.